Home    中文  
 
  • Search
  • lucene Search
  • Citation
  • Fig/Tab
  • Adv Search
Just Accepted  |  Current Issue  |  Archive  |  Featured Articles  |  Most Read  |  Most Download  |  Most Cited

Chinese Journal of Kidney Disease Investigation(Electronic Edition) ›› 2012, Vol. 01 ›› Issue (02): 90-93. doi: 10.3877/cma.j.issn.2095-3216.2012.02.006

• Expert Forum • Previous Articles     Next Articles

Evidence-based treatment for antineutrophil cytoplasmic antibody-associated glomerulonephritis

Min CHEN1, Ming-hui ZHAO1,()   

  1. 1.Renal Division, Peking University First Hospital, Beijing 100034, China
  • Received:2012-10-29 Online:2012-12-18 Published:2024-12-06
  • Contact: Ming-hui ZHAO

Abstract:

Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis is a group of autoimmune diseases. The kidney is the most commonly involved organ, which is termed as ANCAassociated glomerulonephritis. According to the “Kidney Disease: Improving Global Outcomes (KDIGO)”guideline, the treatment for ANCA-associated glomerulonephritis includes initial treatment, maintenance treatment and treatment for relapses. For initial treatment, the first line protocol is the combination of corticosteroids and cyclophosphamide. Rituximab is an alternative choice for cyclophosphamide.Plasma exchange or pulse methylprednisolone are employed in the severe patients. Choices of agents for maintenance therapy mainly include azathioprine and MMF. Treatment for relapse may be either reinstituting of initial therapy or simply increasing the dose of corticosteroids/immunosuppressant,according to the severity of relapse.

Key words: ANCA, Immunosuppressive therapy

京ICP 备07035254号-35
Copyright © Chinese Journal of Kidney Disease Investigation(Electronic Edition), All Rights Reserved.
Tel: 010-66937011 E-mail: zhsbyj@126.com
Powered by Beijing Magtech Co. Ltd